Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study

Cancer Res (2023) 83 (8_Supplement): CT083.

https://doi.org/10.1158/1538-7445.AM2023-CT083

Published: 14 April 2023

View articletitled, Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study

Journal Articles

Abstract 4682: Genomic profiles in gene expression and methylation help define the molecular characteristics of hairy cell leukemia subtypes

Daniel C. Edelman, Holly S. Stevenson, Yonghong Wang, Evgeny Arons, Joshua J. Waterfall, David Petersen, Hong Zhou, Paul S. Meltzer, Robert J. Kreitman

Cancer Res (2017) 77 (13_Supplement): 4682.

https://doi.org/10.1158/1538-7445.AM2017-4682

Published: 01 July 2017

View articletitled, Abstract 4682: Genomic profiles in gene expression and methylation help define the molecular characteristics of hairy cell leukemia subtypes

Journal Articles

Abstract 4595: Moxetumomab pasudotox spares CD4 and CD8 lymphocytes in multiply relapsed hairy cell leukemia patients, while prospective trials of first, second, and later lines of purine analogs show increasing toxicity

Robert J. Kreitman, Maryalice Stetler-Stevenson, Evgeny Arons, Ira Pastan

Cancer Res (2017) 77 (13_Supplement): 4595.

https://doi.org/10.1158/1538-7445.AM2017-4595

Published: 01 July 2017

View articletitled, Abstract 4595: Moxetumomab pasudotox spares CD4 and CD8 lymphocytes in multiply relapsed hairy cell leukemia patients, while prospective trials of first, second, and later lines of purine analogs show increasing toxicity

Journal Articles

Abstract 2710: Molecular and clinical characteristics of IGHV4-34 expressing classic and variant HCL

Evgeny Arons, Katherine Potocka, Maryalice Stetler-Stevenson, Hong Zhou, Mark Raffeld, Mark Sokolsky, Sarah Davies, Robert J. Kreitman

Cancer Res (2017) 77 (13_Supplement): 2710.

https://doi.org/10.1158/1538-7445.AM2017-2710

Published: 01 July 2017

View articletitled, Abstract 2710: Molecular and clinical characteristics of IGHV4-34 expressing classic and variant HCL

Journal Articles

Abstract CT230: Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL)

Alan S. Wayne, Nirali N. Shah, Deepa Bhojwani, Lewis B. Silverman, James A. Whitlock, Maryalice Stetler-Stevenson, Robert J. Kreitman, Trishna Goswami, Ramy Ibrahim, Ira Pastan

Cancer Res (2014) 74 (19_Supplement): CT230.

https://doi.org/10.1158/1538-7445.AM2014-CT230

Published: 01 October 2014

View articletitled, Abstract CT230: Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL)

Journal Articles

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

David J. FitzGerald, Alan S. Wayne, Robert J. Kreitman, Ira Pastan

Cancer Res (2011) 71 (20): 6300–6309.

https://doi.org/10.1158/0008-5472.CAN-11-1374

Published: 12 October 2011

View articletitled, Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

Journal Articles

Abstract 348: Analysis of somatic hypermutations in IGHV genes from Hairy Cell Leukemia Immunoglobulin Heavy Chain rearrangements

Evgeny Arons, Tara Suntum, Laura Roth, Jeffrey Sapolsky, Robert J. Kreitman

Cancer Res (2011) 71 (8_Supplement): 348.

https://doi.org/10.1158/1538-7445.AM2011-348

Published: 15 April 2011

View articletitled, Abstract 348: Analysis of somatic hypermutations in IGHV genes from Hairy Cell Leukemia Immunoglobulin Heavy Chain rearrangements

Journal Articles

Abstract 2125: Somatic hypermutations in hairy cell leukemia suggest a canonical process, except in patients with the poor-prognosis VH4-34 variant

Eugeny Arons, Tara Suntun, Robert J. Kreitman

Cancer Res (2010) 70 (8_Supplement): 2125.

https://doi.org/10.1158/1538-7445.AM10-2125

Published: 15 April 2010

View articletitled, Abstract 2125: Somatic hypermutations in hairy cell leukemia suggest a canonical process, except in patients with the poor-prognosis VH4-34 variant

Journal Articles

Abstract 5606: Preclinical and clinical development of anti-CD25 recombinant immunotoxin LMB-2 in combination with chemotherapy for the treatment of adult T-cell leukemia

Rajat Singh, Yu Jian Zhang, Ira Pastan, Robert J. Kreitman

Cancer Res (2010) 70 (8_Supplement): 5606.

https://doi.org/10.1158/1538-7445.AM10-5606

Published: 15 April 2010

View articletitled, Abstract 5606: Preclinical and clinical development of anti-CD25 recombinant immunotoxin LMB-2 in combination with chemotherapy for the treatment of adult T-cell leukemia

Journal Articles

Abstract 3717: Randomized phase II trial of cladribine with or without immediate rituximab for newly diagnosed or previously treated hairy cell leukemia to eliminate minimal residual disease: Interim report

Robert J. Kreitman, Pierre Noel, Constance M. Yuan, Mark Raffeld, Maryalice Stetler-Stevenson

Cancer Res (2010) 70 (8_Supplement): 3717.

https://doi.org/10.1158/1538-7445.AM10-3717

Published: 15 April 2010

View articletitled, Abstract 3717: Randomized phase II trial of cladribine with or without immediate rituximab for newly diagnosed or previously treated hairy cell leukemia to eliminate minimal residual disease: Interim report

Journal Articles

Minimal residual disease in hairy cell leukemia patients treated by BL22

Evgeny Arons, Inger Margulies, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Maryalice Stetler-Stevenson, Ira Pastan, Robert J. Kreitman

Cancer Res (2006) 66 (8_Supplement): 269.

Published: 15 April 2006

View articletitled, Minimal residual disease in hairy cell leukemia patients treated by BL22

Journal Articles

Complete remissions to anti-CD22 immunotoxin BL22 in Phase I and II trials of patients with chemoresistant hairy cell leukemia may be monitored by assays for soluble CD22 and CD25.

Robert J. Kreitman, Wyndham H. Wilson, Maryalice Stetler-Stevenson, David Jp Fitzgerald, Ira Pastan

Cancer Res (2006) 66 (8_Supplement): 1328.

Published: 15 April 2006

View articletitled, Complete remissions to anti-CD22 immunotoxin BL22 in Phase I and II trials of patients with chemoresistant hairy cell leukemia may be monitored by assays for soluble CD22 and CD25.

Journal Articles

Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies

Ralph F. Alderson, Enrique Escandon, Tianling Chen, Peter Yeung, Douglas Hodges, Wei Geng, David J P Fitzgerald, Robert J. Kreitman, Ira Pastan, Judy A. Fox

Cancer Res (2006) 66 (8_Supplement): 877.

Published: 15 April 2006

View articletitled, Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies

Journal Articles

Elevation of soluble IRTA2/FcRH5 (CD307) level in chronic lymphocytic leukemia hairy cell leukemia, mantle cell lymphoma and multiple myeloma

Tomoko Ise, Satoshi Nagata, Robert J. Kreitman, Wyndham H. Wilson, Alan S. Wayne, Maryalice Stetler-Stevenson, Michael R. Bishop, David A. Scheinberg, Laura Rassenti, Thomas J. Kipps, Robert A. Kyle, Diane F. Jelinek, Ira Pastan

Cancer Res (2006) 66 (8_Supplement): 680.

Published: 15 April 2006

View articletitled, Elevation of soluble IRTA2/FcRH5 (CD307) level in chronic lymphocytic leukemia hairy cell leukemia, mantle cell lymphoma and multiple myeloma

Journal Articles

Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy

Mitomu Kioi, Satoru Takahashi, Mariko Kawakami, Koji Kawakami, Robert J. Kreitman, Raj K. Puri

Cancer Res (2005) 65 (18): 8388–8396.

https://doi.org/10.1158/0008-5472.CAN-05-1043

Published: 15 September 2005

View articletitled, Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy

Journal Articles

HA22 (R490A) is a recombinant immunotoxin with increased anti-tumor activity and therapeutic index

Sookhee Bang, Robert J. Kreitman, David Fitzgerald, Ira Pastan

Cancer Res (2004) 64 (7_Supplement): 144.

Published: 01 April 2004

View articletitled, HA22 (R490A) is a recombinant immunotoxin with increased anti-tumor activity and therapeutic index

Journal Articles

Characterization of expanded cytotoxic T-cell populations in patients with hairy cell leukemia receiving immunotoxin BL22.

Evgeny Arons, Maryalice Stetler-Stevenson, Mark Raffeld, Lynn Sorbora, Robert J. Kreitman

Cancer Res (2004) 64 (7_Supplement): 498–499.

Published: 01 April 2004

View articletitled, Characterization of expanded cytotoxic T-cell populations in patients with hairy cell leukemia receiving immunotoxin BL22.

Journal Articles

Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity

Masanori Onda, Satoshi Nagata, Yasuo Tsutsumi, James J. Vincent, Qing-cheng Wang, Robert J. Kreitman, Byungkook Lee, Ira Pastan

Cancer Res (2001) 61 (13): 5070–5077.

Published: 01 July 2001

View articletitled, Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity

Journal Articles

Complete Regression of Established Human Glioblastoma Tumor Xenograft by Interleukin-4 Toxin Therapy

Syed R. Husain, Niti Behari, Robert J. Kreitman, Ira Pastan, Raj K. Puri

Cancer Res (1998) 58 (16): 3649–3653.

Published: 01 August 1998

View articletitled, Complete Regression of Established Human Glioblastoma Tumor Xenograft by Interleukin-4 Toxin Therapy

Journal Articles

Accumulation of a Recombinant Immunotoxin in a Tumor in Vivo: Fewer Than 1000 Molecules per Cell Are Sufficient for Complete Responses

Robert J. Kreitman, Ira Pastan

Cancer Res (1998) 58 (5): 968–975.

Published: 01 March 1998

View articletitled, Accumulation of a Recombinant Immunotoxin in a Tumor in Vivo: Fewer Than 1000 Molecules per Cell Are Sufficient for Complete Responses

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study

Abstract 4682: Genomic profiles in gene expression and methylation help define the molecular characteristics of hairy cell leukemia subtypes

Abstract 4595: Moxetumomab pasudotox spares CD4 and CD8 lymphocytes in multiply relapsed hairy cell leukemia patients, while prospective trials of first, second, and later lines of purine analogs show increasing toxicity

Abstract 2710: Molecular and clinical characteristics of IGHV4-34 expressing classic and variant HCL

Abstract CT230: Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL)

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

Abstract 348: Analysis of somatic hypermutations in IGHV genes from Hairy Cell Leukemia Immunoglobulin Heavy Chain rearrangements

Abstract 2125: Somatic hypermutations in hairy cell leukemia suggest a canonical process, except in patients with the poor-prognosis VH4-34 variant

Abstract 5606: Preclinical and clinical development of anti-CD25 recombinant immunotoxin LMB-2 in combination with chemotherapy for the treatment of adult T-cell leukemia

Abstract 3717: Randomized phase II trial of cladribine with or without immediate rituximab for newly diagnosed or previously treated hairy cell leukemia to eliminate minimal residual disease: Interim report

Minimal residual disease in hairy cell leukemia patients treated by BL22

Complete remissions to anti-CD22 immunotoxin BL22 in Phase I and II trials of patients with chemoresistant hairy cell leukemia may be monitored by assays for soluble CD22 and CD25.

Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies

Elevation of soluble IRTA2/FcRH5 (CD307) level in chronic lymphocytic leukemia hairy cell leukemia, mantle cell lymphoma and multiple myeloma

Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy

HA22 (R490A) is a recombinant immunotoxin with increased anti-tumor activity and therapeutic index

Characterization of expanded cytotoxic T-cell populations in patients with hairy cell leukemia receiving immunotoxin BL22.

Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity

Complete Regression of Established Human Glioblastoma Tumor Xenograft by Interleukin-4 Toxin Therapy

Accumulation of a Recombinant Immunotoxin in a Tumor in Vivo: Fewer Than 1000 Molecules per Cell Are Sufficient for Complete Responses

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only